Recent Updates
Recently added Catalysts

REGN9220

Phase 1

Diffuse Large B-Cell Lymphoma (DLBCL) | Small molecule | Other |Regeneron Pharmaceuticals, Inc.|Trials Updated: Oct 21, 2026

REGN9220 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

REGN9220 clinical trials

REGN9220 · 1 trial · 1 indication

Phase 1 1
NCT07887750REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Diffuse Large B-Cell Lymphoma (DLBCL)
NOT YET_RECRUITING36 Analytics
PHASE1NOT YET_RECRUITING
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
Diffuse Large B-Cell Lymphoma (DLBCL)
NCT0788775036
Unlock trial analytics

Study Endpoints

Primary Endpoints

Occurrence of Dose-Limiting Toxicities (DLTs) during the DLT observation period
Up to 28 days
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Up to approximately 2 years
Severity of TEAEs
Up to approximately 2 years

Secondary Endpoints

Concentration of REGN9220 in serum when given in combination with odronextamab
Up to approximately 2 years
Concentration of odronextamab in serum when given in combination with REGN9220
Up to approximately 2 years
Occurrence of Anti-Drug Antibodies (ADA) to REGN9220
Up to approximately 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
REGN9220 + OdronextamabEXPERIMENTAL -

Interventions

NameTypeDescription
REGN9220DRUGAdministered per the protocol
OdronextamabDRUGAdministered per the protocol
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: 1. Documented Cluster of Differentiation (CD)20+ aggressive B-cell non-Hodgkin lymphoma that is relapsed or refractory 2. Measurable disease on cross sectional imaging 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 4. Adequate organ function (hematologic...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 21, 2026NCT07887750NEW_TRIAL: changed
LOWOct 21, 2026NCT07887750NEW_TRIAL: changed
LOWOct 21, 2026NCT07887750NEW_TRIAL: changed

Explore more on BiopharmaWatch

Regeneron Pharmaceuticals, Inc. (REGN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with RCompanies A to ZEvery biotech and pharma company we track